Biotech · Private company
Kiniksa Pharmaceuticals, Ltd.
Track this companyFree. Adds Kiniksa Pharmaceuticals, Ltd. to your Dealase workspace and tells you when its record changes.
Clinical trials102 recruiting or active
Pipeline programs4From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline4
- KPL-404Phase 2 · Arthritis, RheumatoidClinicalTrials.gov · fetched Nov 12, 2026
- mavrilimumabPhase 2 · Giant Cell ArteritisClinicalTrials.gov · fetched Nov 12, 2026
- prednisonePhase 2 · Giant Cell ArteritisClinicalTrials.gov · fetched Nov 12, 2026
- KPL-404Phase 1 · Healthy VolunteersClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials10
- Transition to KPL-387 Monotherapy Dosing & Administration StudyPHASE2 · RECRUITING · started Mar 25, 2026ClinicalTrials.gov NCT07288216 · fetched Nov 12, 2026
- Phase 2/3 Study of Participants With Recurrent Pericarditis Evaluating the Efficacy and Safety of KPL-387PHASE2_PHASE3 · RECRUITING · started Jul 25, 2025ClinicalTrials.gov NCT07010159 · fetched Nov 12, 2026
- A Study to Evaluate the Efficacy and Safety of Abiprubart in Participants With Sjögren's DiseasePHASE2 · TERMINATED · started Jul 17, 2024ClinicalTrials.gov NCT06531395 · fetched Nov 12, 2026
- Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase InhibitorPHASE2 · COMPLETED · started Dec 14, 2021ClinicalTrials.gov NCT05198310 · fetched Nov 12, 2026
- Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammationPHASE2_PHASE3 · COMPLETED · started Jul 28, 2020ClinicalTrials.gov NCT04447469 · fetched Nov 12, 2026
- Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammationPHASE2 · COMPLETED · started May 20, 2020ClinicalTrials.gov NCT04492514 · fetched Nov 12, 2026
- Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of KPL-404 in Healthy SubjectsPHASE1 · COMPLETED · started Oct 22, 2019ClinicalTrials.gov NCT04497662 · fetched Nov 12, 2026
- A Study to Assess the Efficacy, Safety, and Tolerability of KPL-716 in Reducing Pruritus in Chronic Pruritic DiseasesPHASE2 · COMPLETED · started May 29, 2019ClinicalTrials.gov NCT03858634 · fetched Nov 12, 2026
- Study to Assess the Efficacy, Safety, and Tolerability of Vixarelimab in Reducing Pruritus in Prurigo NodularisPHASE2 · COMPLETED · started Mar 11, 2019ClinicalTrials.gov NCT03816891 · fetched Nov 12, 2026
- KPL-301 for Subjects With Giant Cell ArteritisPHASE2 · COMPLETED · started Sep 20, 2018ClinicalTrials.gov NCT03827018 · fetched Nov 12, 2026